These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37405515)

  • 1. Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data.
    Cella D; Johansson P; Ueda Y; Tomazos I; Gustovic P; Wang A; Patel AS; Schrezenmeier H
    J Patient Rep Outcomes; 2023 Jul; 7(1):63. PubMed ID: 37405515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
    Almeida AM; Bedrosian C; Cole A; Muus P; Schrezenmeier H; Szer J; Rosse WF
    Intern Med J; 2017 Sep; 47(9):1026-1034. PubMed ID: 28608499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
    Höchsmann B; de Fontbrune FS; Lee JW; Kulagin AD; Hillmen P; Wilson A; Marantz JL; Schrezenmeier H
    Eur J Haematol; 2022 Sep; 109(3):197-204. PubMed ID: 35390189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study.
    Cella D; Sarda SP; Hsieh R; Fishman J; Hakimi Z; Hoffman K; Al-Adhami M; Nazir J; Cutts K; Lenderking WR
    Ann Hematol; 2022 Sep; 101(9):1905-1914. PubMed ID: 35869984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
    Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
    Schrezenmeier H; Kulasekararaj A; Mitchell L; de Latour RP; Devos T; Okamoto S; Wells R; Popoff E; Cheung A; Wang A; Tomazos I; Patel Y; Lee JW
    Ann Hematol; 2024 Jan; 103(1):5-15. PubMed ID: 37804344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data.
    Panse J; Wilson K; Fishman J; Wojciechowski P; Wdowiak M; Horneff R; Patriquin CJ; Oliver M; Hakimi Z
    Eur J Haematol; 2023 Jul; 111(1):72-83. PubMed ID: 36965105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry.
    Schrezenmeier H; Röth A; Araten DJ; Kanakura Y; Larratt L; Shammo JM; Wilson A; Shayan G; Maciejewski JP
    Ann Hematol; 2020 Jul; 99(7):1505-1514. PubMed ID: 32390114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
    Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
    Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)-a report on phase III.
    Niedeggen C; Singer S; Groth M; Petermann-Meyer A; Röth A; Schrezenmeier H; Höchsmann B; Brümmendorf TH; Panse J
    Ann Hematol; 2019 Jul; 98(7):1547-1559. PubMed ID: 31115593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
    Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
    Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
    Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
    Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria.
    Weitz I; Meyers G; Lamy T; Cahn JY; Uranga MT; García Vela JA; Sanz MA; Severino B; Kelly RJ; Hillmen P; Hill A
    Intern Med J; 2013 Mar; 43(3):298-307. PubMed ID: 22909078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features and quality of life assessment in Japanese PNH patients enrolled in the International PNH Registry].
    Sakurai M; Okamoto S
    Rinsho Ketsueki; 2017; 58(11):2261-2267. PubMed ID: 29212979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life.
    Panse J; Sicre de Fontbrune F; Burmester P; Piggin M; Matos JE; Costantino H; Wilson K; Hakimi Z; Nazir J; Desgraz R; Fishman J; Persson E; Kulasekararaj A
    Eur J Haematol; 2022 Oct; 109(4):351-363. PubMed ID: 35746830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria.
    Schwartz CE; Stark RB; Borowiec K; Nolte S; Myren KJ
    Orphanet J Rare Dis; 2021 Sep; 16(1):389. PubMed ID: 34526067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
    de Latour RP; Szer J; Weitz IC; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro CM; Nishimori H; Ajayi T; Al-Adhami M; Deschatelets P; Francois C; Grossi F; Risitano AM; Hillmen P
    Lancet Haematol; 2022 Sep; 9(9):e648-e659. PubMed ID: 36055332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study.
    Patriquin CJ; Bogdanovic A; Griffin M; Kelly RJ; Maciejewski JP; Mulherin B; Peffault de Latour R; Röth A; Selvaratnam V; Szer J; Al-Adhami M; Horneff R; Tan L; Yeh M; Panse J
    Adv Ther; 2024 May; 41(5):2050-2069. PubMed ID: 38573482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
    Brodsky RA; Young NS; Antonioli E; Risitano AM; Schrezenmeier H; Schubert J; Gaya A; Coyle L; de Castro C; Fu CL; Maciejewski JP; Bessler M; Kroon HA; Rother RP; Hillmen P
    Blood; 2008 Feb; 111(4):1840-7. PubMed ID: 18055865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Eculizumab in patients with paroxysmal nocturnal hemoglobinuria: a real-world study in China].
    Wang LY; Hu QL; Chen M; Yang C; Han B
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):184-189. PubMed ID: 38604796
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.